ஜூர்கன் எக்கர்டத் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜூர்கன் எக்கர்டத். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜூர்கன் எக்கர்டத் Today - Breaking & Trending Today

Kojin Therapeutics Debuts to Solve Difficult Diseases Through Cell Behavior

Published: Jun 09, 2021
By Mark Terry
Kojin Therapeutics
launched with a $60 million Series A to initially focus on oncology and cell state biology. The round was led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital. Participants included Leaps by Bayer, AbbVie, Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices.
The approach came out of the
laboratoryof Stuart Schreiber, Harvard University professor and co-founder of the Broad Institute. Co-founders of Kojin include Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan. The company’s technology is ferroptosis-based drug discovery, which is to say, iron-dependent cell death. Kojin says that difficult-to-treat diseases, which includes drug-resistant cancers, involve diseased cells that are sensitive to ferroptosis. ....

United States , Al Iskandariyah , Harvard University , Dana Farber Cancer Institute , Jurgen Eckhardt , Amir Nashat , Benjamin Cravatt , Stephanie Dougan , Joel Barrish , Steve Davidsen , Nagesh Mahanthappa , Susan Langer , Vasanthi Viswanathan , Nortonb Gilula , Stuart Schreiber , Kay Ahn , Sean Morrison , Scripps Research Institute , Broad Institute , Sarcoma Center At Dana Farber , Harvard Medical School , Ludwig Center At Dana Farber Harvard Cancer , Cathay Health , Children Medical Center Research Institute , Department Of Chemistry , Schreiber Lab ,

Huma raises $130 million financing to scale its digital health platform for better care and research

LONDONÂ and NEW YORK
Â , May 12, 2021 /PRNewswire/ Â Huma Therapeutics Limited today announces the completion of its latest funding round with financing of approximately $130 million. The investment will scale Huma s modular platform which can power digital hospitals at home nationally, and support the pharmaceutical and research industries to run the largest ever decentralized clinical trials. Huma s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research.
Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV , Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders. ....

United Kingdom , City Of , Jonathan Machado , Dan Vahdat , Alan Milburn , Keiji Kojima , Michael Diekmann , Ignazio Castiglioni , Juergen Eckhardt , Gen Tsuchikawa , Claudia Suessmuth Dyckerhoff , Nikesh Arora , Huma Therapeutics , World Economic Forum Global Innovators Community , Innovation Growth Ventures Co Ltd , Daiwa Capital Holdings , Prudential Regulation Authority , United Kingdom Health , University Of Cambridge , Goldman Sachs International , Stanford University Center , Technology Innovation Fund , Sony Innovation Fund , Financial Conduct Authority , Johns Hopkins Bloomberg School Of Public Health , Formative Research ,

Huma, which uses AI and biomarkers to monitor patients and for medical research, raises $130M – TechCrunch

Huma, which uses AI and biomarkers to monitor patients and for medical research, raises $130M
While much of the world eagerly watches to see if the vaccination rollout helps curb and eventually stamp out Covid-19, one of the companies that has been helping to manage the spread of the virus is announcing a big round of funding on the heels for strong demand for its technology.
Huma, which combines data from biomarkers with predictive algorithms both to help monitor patients, and uses the same technology to help researchers and pharmaceutical companies run clinical trials, has closed an equity round of $130 million, a Series C that the company can extend to $200 million by way of a $70 million debt line if it chooses. ....

United Kingdom , City Of , Juergen Eckhardt , Dan Vahdat , Keiji Kojima , Michael Diekmann , Nikesh Arora , Sony Innovation Fund , Technology Innovation Fund , London Based Huma , Hitachi Ventures , Samsung Next , Unilever Ventures , Innovation Fund , Cambridge Fenland , Smart Life , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ஜூர்கன் எக்கர்டத் , டான் வஹதத் , கேஜி கோஜிமா , மைக்கேல் டிெக்மன்ன் , நிகேஷ் அரோரா , சோனி கண்டுபிடிப்பு நிதி , தொழில்நுட்பம் கண்டுபிடிப்பு நிதி , சாப்ட் பேங்க் ,

British health tech firm Huma secures $130 million in Series C round

The funds will be used to scale its remote monitoring platform. ....

United Kingdom , Juergen Eckhardt , Dan Vahdat , Alan Milburn , Claudia Suessmuth Dyckerhoff , Michael Diekmann , Nikesh Arora , Datos Health , Sony Innovation Fund , Technology Innovation Fund , Huma Therapeutics Ltd , Hitachi Ventures , Unilever Ventures , Innovation Fund , Tarilian Laser Technologies , Medial Earlysign , Royal Philips , Philips Medical Tablet , ஒன்றுபட்டது கிஂக்டம் , ஜூர்கன் எக்கர்டத் , டான் வஹதத் , ஆலன் மில்பர்ன் , மைக்கேல் டிெக்மன்ன் , நிகேஷ் அரோரா , டேட்டோஸ் ஆரோக்கியம் , சாப்ட் பேங்க் ,

Edifice, a Healthcare Disruptor spun out of Stanford, Raises $12 Million to Reinvent Immune Health, Improve Healthspan, and Change Course of Aging

Edifice, a Healthcare Disruptor spun out of Stanford, Raises $12 Million to Reinvent Immune Health, Improve Healthspan, and Change Course of Aging
News provided by
Share this article
Share this article
SAN MATEO, Calif., April 22, 2021 /PRNewswire/ Edifice Health, a Silicon Valley emerging company in immunological health and personalized nutrition, today announced a $12 Million investment, led by
Leaps by Bayer.
Through its highly-differentiated approach, Edifice aims to harness previously unattainable insights into the root causes of chronic diseases of aging, followed by delivering highly personalized interventions to improve inflammatory and immune health, and extend healthspan.
Globally, about 71% of annual deaths are attributable to non-communicable diseases of aging, which include cancer, cardiovascular diseases, Type II diabetes, neurodegenerative disorders, and depression. According to the U.S. Centers for Disease Control (CDC), 90% of the n ....

Santosh Padki , Wolfgang Daum , David Furman , Eric Verdin , Juergen Eckhardt , Mark Davis , Robert Tibshirani , Bayer Naveen Krishnan , Edifice Health Inc , Buck Institute For Research On , Longevity Incubator Fund , Bayer Ag , Institute For Immunity , Paladin Capital Group , Us Centers For Disease Control , Vp Corporate Development , Edifice Health , Paladin Group Paul Conley , Stanford University , Performance Impact Venture Fund , Silicon Valley , Disease Control , Stanford Project , National Institute , Capital Group , Vertical Venture Partners ,